login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
ARBUTUS BIOPHARMA CORP (ABUS) Stock News
NASDAQ:ABUS - Nasdaq -
CA03879J1003
-
Common Stock
- Currency: USD
3.21
-0.03 (-0.93%)
Summary
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ABUS Latest News, Press Relases and Analysis
All
Press Releases
a month ago - By: Arbutus Biopharma Corporation
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
a month ago - By: Arbutus Biopharma Corporation
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
2 months ago - By: Zacks Investment Research
- Mentions:
MRSN
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
2 months ago - By: Arbutus Biopharma Corporation
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
2 months ago - By: Arbutus Biopharma Corporation
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
2 months ago - By: Zacks Investment Research
- Mentions:
EDIT
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
3 months ago - By: Arbutus Biopharma Corporation
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
3 months ago - By: Arbutus Biopharma Corporation
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
3 months ago - By: Zacks Investment Research
Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know
3 months ago - By: Arbutus Biopharma Corporation
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
3 months ago - By: Arbutus Biopharma Corporation
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
4 months ago - By: Zacks Investment Research
All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy
4 months ago - By: Zacks Investment Research
- Mentions:
AVAH
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
4 months ago - By: Zacks Investment Research
- Mentions:
BMY
Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates
4 months ago - By: Arbutus Biopharma Corporation
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
4 months ago - By: Arbutus Biopharma Corporation
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
5 months ago - By: Arbutus Biopharma Corporation
- Mentions:
ROIV
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
5 months ago - By: Arbutus Biopharma Corporation
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
5 months ago - By: Arbutus Biopharma Corporation
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
6 months ago - By: Arbutus Biopharma Corporation
Arbutus Provides 2025 Corporate and Financial Update
6 months ago - By: Arbutus Biopharma Corporation
Arbutus Provides 2025 Corporate and Financial Update
8 months ago - By: Whitefort Capital Management, LP
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors
8 months ago - By: Arbutus Biopharma Corporation
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
8 months ago - By: Arbutus Biopharma Corporation
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
8 months ago - By: Benzinga
- Mentions:
NOG
AVAV
DLB
ENR
...
Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday
8 months ago - By: Arbutus Biopharma Corporation
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
8 months ago - By: Arbutus Biopharma Corporation
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
8 months ago - By: Arbutus Biopharma Corporation
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
8 months ago - By: Barinthus Biotherapeutics
- Mentions:
BRNS
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
8 months ago - By: Arbutus Biopharma Corporation
Arbutus to Present at Jefferies London Healthcare Conference
8 months ago - By: Arbutus Biopharma Corporation
Arbutus to Present at Jefferies London Healthcare Conference
9 months ago - By: Arbutus Biopharma Corporation
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
9 months ago - By: Arbutus Biopharma Corporation
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
9 months ago - By: Arbutus Biopharma Corporation
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
9 months ago - By: Arbutus Biopharma Corporation
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
9 months ago - By: Arbutus Biopharma Corporation
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
9 months ago - By: Arbutus Biopharma Corporation
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
10 months ago - By: Benzinga
- Mentions:
ALNY
MRNA
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine
Please enable JavaScript to continue using this application.